Chikungunya Virus Vaccine Candidate Incorporating Synergistic Mutations Is Attenuated and Protects Against Virulent Virus Challenge
The Journal of Infectious Diseases · 2023
DOI: 10.1093/infdis/jiac066 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Journal of Infectious Diseases, 2023. Verfasst von Anthony J Lentscher und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Microbiology and Molecular Genetics, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA. Hauptthemen laut MEDLINE: Chikungunya virus, Chikungunya Fever, Viral Vaccines. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 22 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIAID NIH HHS, National Institute of Allergy and Infectious Disease, UPMC Children’s Hospital of Pittsburgh.
Abstract (Originalsprache)
Background
Chikungunya virus (CHIKV) is an arbovirus that periodically emerges to cause large epidemics of arthritic disease. Although the robust immunity elicited by live-attenuated virus (LAV) vaccine candidates makes them attractive, CHIKV vaccine development has been hampered by a high threshold for acceptable adverse events.
Methods
We evaluated the vaccine potential of a recently described LAV, skeletal muscle-restricted virus (SKE), that exhibits diminished replication in skeletal muscle due to insertion of target sequences for skeletal muscle-specific miR-206. We also evaluated whether these target sequences could augment safety of an LAV encoding a known attenuating mutation, E2 G82R. Attenuation of viruses containing these mutations was compared with a double mutant, SKE G82R.
Results
SKE was attenuated in both immunodeficient and immunocompetent mice and induced a robust neutralizing antibody response, indicating its vaccine potential. However, only SKE G82R elicited diminished swelling in immunocompetent mice at early time points postinoculation, indicating that these mutations synergistically enhance safety of the vaccine candidate.
Conclusions
These data suggest that restriction of LAV replication in skeletal muscle enhances tolerability of reactogenic vaccine candidates and may improve the rational design of CHIKV vaccines.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Microbiology and Molecular Genetics, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA.
- Institute for Infection, Inflammation, and Immunity, UPMC Children's Hospital of Pittsburgh, Pittsburgh, Pennsylvania, USA.
- Department of Biology, Seton Hill University, Greenburg, Pennsylvania, USA.
- Department of Pediatrics, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA.
ORCID-Profile: Terence S Dermody
Förderung
- NIAID NIH HHS
- National Institute of Allergy and Infectious Disease
- UPMC Children’s Hospital of Pittsburgh
- Heinz Endowments
- NIH
Zitieren
APA
Lentscher, A. J., McAllister, N., Griswold, K. A., Martin, J. L., Welsh, O. L., Sutherland, D. M., Silva, L. A., & Dermody, T. S. (2023). Chikungunya Virus Vaccine Candidate Incorporating Synergistic Mutations Is Attenuated and Protects Against Virulent Virus Challenge. The Journal of Infectious Diseases. https://doi.org/10.1093/infdis/jiac066
Vancouver
Lentscher AJ, McAllister N, Griswold KA, Martin JL, Welsh OL, Sutherland DM, et al. Chikungunya Virus Vaccine Candidate Incorporating Synergistic Mutations Is Attenuated and Protects Against Virulent Virus Challenge. The Journal of Infectious Diseases. 2023. doi:10.1093/infdis/jiac066
BibTeX
@article{Lentscher2023,
author = {Lentscher, Anthony J and McAllister, Nicole and Griswold, Kira A and Martin, James L and Welsh, Olivia L and Sutherland, Danica M and Silva, Laurie A and Dermody, Terence S},
title = {Chikungunya Virus Vaccine Candidate Incorporating Synergistic Mutations Is Attenuated and Protects Against Virulent Virus Challenge},
journal = {The Journal of Infectious Diseases},
year = {2023},
doi = {10.1093/infdis/jiac066}
}
EUVIMED